公开(公告)号：PL1730146T3

公开(公告)日：2011-10-31

申请号：PL05756052

申请日：2005-03-30

Applicant: VERTEX PHARMA

Inventor： SALITURO FRANCESCO ,  FARMER LUC ,  BETHIEL RANDY ,  HARRINGTON EDMUND ,  GREEN JEREMY ,  COURT JOHN ,  COME JON ,  LAUFFER DAVID ,  ARONOV ALEX ,  BINCH HAYLEY ,  BOYALL DEAN ,  CHARRIER JEAN-DAMIEN ,  EVERITT SIMON ,  FRAYSSE DAMIEN ,  MORTIMORE MICHAEL ,  PIERARD FRANCOISE ,  ROBINSON DANIEL ,  PINDER JOANNE ,  WANG TIANSHENG ,  PIERCE ALBERT ,  WANG JIAN

IPC: C07D471/04 ,  C07D519/00

公开(公告)号：AT526328T

公开(公告)日：2011-10-15

申请号：AT08731839

申请日：2008-03-10

Applicant: VERTEX PHARMA

Inventor： PIERCE ALBERT ,  COME JON ,  COURT JOHN ,  GAO HUAI ,  HENKEL GREGORY ,  LIU MICHAEL ,  NEUBERGER TIMOTHY

IPC: C07D471/04

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

公开(公告)号：HK1138572A1

公开(公告)日：2010-08-27

申请号：HK10103874

申请日：2010-04-21

Applicant: VERTEX PHARMA

Inventor： PIERCE ALBERT ,  COME JON ,  COURT JOHN ,  GAO HUAI ,  HENKEL GREGORY ,  LIU MICHAEL ,  NEUBERGER TIMOTHY

IPC: C07D20060101 ,  A61K20060101 ,  A61P20060101

Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.

公开(公告)号：AU2006202124B2

公开(公告)日：2010-01-21

申请号：AU2006202124

申请日：2006-05-19

Applicant: VERTEX PHARMA

Inventor： O'MALLEY ETHAN ,  BHISETTI GOVINDA RAO ,  PERNI ROBERT ,  COURT JOHN

IPC: C07D203/00 ,  A61K31/13 ,  A61K38/00 ,  A61P31/12 ,  C07D205/00 ,  C07K5/103 ,  C07K7/06

公开(公告)号：AU2005228904A1

公开(公告)日：2005-10-13

申请号：AU2005228904

申请日：2005-03-30

Applicant: VERTEX PHARMA

Inventor： COURT JOHN ,  ROBINSON DANIEL ,  CHARRIER JEAN-DAMIEN ,  FRAYSSE DAMIEN ,  MORTIMORE MICHAEL ,  LAUFFER DAVID ,  BETHIEL RANDY ,  FARMER LUC ,  HARRINGTON EDMUND ,  COME JON ,  GREEN JEREMY ,  EVERITT SIMON ,  BINCH HAYLEY ,  SALITURO FRANCESCO ,  PIERARD FRANCOISE ,  ARONOV ALEX ,  BOYALL DEAN

IPC: C07D471/04 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I), which are inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

公开(公告)号：CA2405043A1

公开(公告)日：2001-10-11

申请号：CA2405043

申请日：2001-03-29

Applicant: VERTEX PHARMA

Inventor： O'MALLEY ETHAN ,  BHISETTI GOVINDA RAO ,  COURT JOHN ,  PERNI ROBERT

IPC: C12N9/99 ,  A61K31/13 ,  A61K31/7052 ,  A61K38/00 ,  A61K38/21 ,  A61K45/00 ,  A61P31/14 ,  C07K5/103 ,  C07K7/06 ,  C07K5/117 ,  A61K38/07 ,  A61L2/16

Abstract: The present invention relates to compounds that are useful as protease inhibitors, particularly as serine protease inhibitors, and more particularl y as hepatitis C NS3 protease inhibitors. As such, they act by interfering wit h the life cycle of the hepatitis C virus and are also useful as antiviral agents. This invention also relates to pharmaceutical compositions comprisin g these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HCV NS3 protease activity and consequently, may be advantageously used as therapeutic agents against the hepatitis C virus and other viruses that are dependent upon a serine protease for proliferation. This invention also relates to methods fo r inhibiting the activity of proteases, including hepatitis C virus NS3 protea se and other serine proteases, using the compounds of this invention and relate d compounds.

公开(公告)号：ES2604667T3

公开(公告)日：2017-03-08

申请号：ES10726760

申请日：2010-06-17

Applicant: VERTEX PHARMA

Inventor： CHARIFSON PAUL ,  CLARK MICHAEL ,  BANDARAGE UPUL ,  BETHIEL RANDY ,  COURT JOHN ,  DENG HONGBO ,  DRUTU IOANA ,  DUFFY JOHN ,  FARMER LUC ,  GAO HUAI ,  GU WENXIN ,  JACOBS DYLAN ,  KENNEDY JOSEPH ,  LEDEBOER MARK ,  LEDFORD BRIAN ,  MALTAIS FRANCOIS ,  PEROLA EMANUELE ,  WANG TIANSHENG ,  WANNAMAKER M ,  BYRN RANDAL ,  ZHOU YI ,  LIN CHAO ,  JIANG MIN ,  GERMANN URSULA ,  JONES STEVEN ,  SALITURO FRANCESCO G ,  KWONG ANN DAK-YEE

IPC: A61K31/506 ,  A61P31/16

Abstract: Un compuesto de la fórmula:**Fórmula** o una sal farmacéuticamente aceptable del mismo.

公开(公告)号：DK2332940T3

公开(公告)日：2013-02-11

申请号：DK10182365

申请日：2005-03-30

Applicant: VERTEX PHARMA

Inventor： WANG JIAN ,  SALITURO FRANCESCO ,  FARMER LUC ,  BETHIEL RANDY ,  HARRINGTON EDMUND ,  GREEN JEREMY ,  COURT JOHN ,  COME JON ,  LAUFFER DAVID ,  ARONOV ALEX ,  BINCH HAYLEY ,  BOYALL DEAN ,  CHARRIER JEAN-DAMIEN ,  EVERITT SIMON ,  FRAYSSE DAMIEN ,  MORTIMORE MICHAEL ,  PIERARD FRANCOISE ,  ROBINSON DANIEL ,  PINDER JOANNE ,  WANG TIANSHENG ,  PIERCE ALBERT

IPC: C07D471/04 ,  C07D519/00

公开(公告)号：PT2332940E

公开(公告)日：2013-01-30

申请号：PT10182365

申请日：2005-03-30

Applicant: VERTEX PHARMA

Inventor： MORTIMORE MICHAEL ,  COURT JOHN ,  WANG JIAN ,  SALITURO FRANCESCO ,  WANG TIANSHENG ,  CHARRIER JEAN-DAMIEN ,  FARMER LUC ,  BETHIEL RANDY ,  HARRINGTON EDMUND ,  GREEN JEREMY ,  COME JON ,  LAUFFER DAVID ,  BINCH HAYLEY ,  EVERITT SIMON ,  FRAYSSE DAMIEN ,  ROBINSON DANIEL ,  PINDER JOANNE ,  PIERCE ALBERT ,  ARONOV ALEX ,  PIERARD FRANCOISE

IPC: C07D471/04 ,  C07D519/00

公开(公告)号：NZ575548A

公开(公告)日：2011-09-30

申请号：NZ57554807

申请日：2007-09-18

Applicant: VERTEX PHARMA

Inventor： ARONOV ALEXANDER ,  COME JON ,  COURT JOHN ,  DEININGER DAVID ,  LAUFFER DAVID ,  LI PAN ,  MCGINTY KIRA ,  NANTHAKUMAR SUGANTHINI ,  STAMOS DEAN ,  TANNER KIRK

IPC: C07D497/04 ,  A61K31/433 ,  A61P35/00 ,  C07D513/04

Abstract: Disclosed is a 5-mercapto-4-amino-4H-1,2,4-triazol-3-yl)ethylcarbamate of formula (I) or a salt, prodrug thereof, wherein LA, Y1 or Y2, Z, R1, R2, R3 and X is defined in the specification for treating colon cancer, gastric adenocarcinoma, bladder cancer, breast cancer, kidney cancer, liver cancer, lung cancer, thyroid cancer, cancer of the head and neck, prostate cancer, pancreatic cancer, cancer of the CNS, gliobastoma, or atherosclerosis.